Recognition, management and prophylaxis of endocarditis

Drugs

Volumn 54, Issue 5, 1997, Pages 730-744

  Stamboulian, Daniel ^a,b   Carbone, Edith ^a  

^a Centro de Estudios Infectologicos   (Argentina)

^b Fundacion Centro de Estudios Infectologicos   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; PENICILLIN G;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL ENDOCARDITIS; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ENDOCARDITIS; ENTEROCOCCUS; HEART VALVE PROSTHESIS; HUMAN; LABORATORY DIAGNOSIS; MORBIDITY; MORTALITY; MYCOSIS; PATIENT COMPLIANCE; REVIEW; STAPHYLOCOCCUS; STREPTOCOCCUS;

BACTERIA (MICROORGANISMS); ENTEROCOCCUS; STAPHYLOCOCCI; STAPHYLOCOCCUS; STREPTOCOCCUS;

EID: 0030710185     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754050-00005     Document Type: Review

References (144)

1. Steckelberg JM, Melton LJ, Ilstrup DM, et al. Influence of referral bias on the apparent clinical spectrum of infective endocarditis. Am J Med 1990; 88: 582-8
2. Bayliss R, Clarke C, Oakley CM, et al. Incidence, mortality and prevention of infective endocarditis. J R Coll Phys Lond 1986; 20: 15-20
3. Selton-Suty C, Hoen B, Grentzinger A, et al. Clinical and bacteriological characteristics of infective endocarditis in the elderly. Heart 1997; 77: 260-3
4. Gross PA, Levine J. Infections in the elderly. In: Wenzel RP, editor. Prevention and control of nosocomial infections. Baltimore: Williams and Wilkins, 1993: 897-992
5. Chambers HF, Morris DL, Tauber MG, et al. Cocaine use and the risk for endocarditis in intravenous drug users. Ann Intern Med 1987 Jun; 106 (6): 833-6
6. Bayer A. Infective endocarditis. Clin Infect Dis 1993; 17: 313-22
7. Douglas JL, Cobbs G. Prosthetic valve endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 375-96
8. Braimbridge MV, Eykyn SJ. Prosthetic valve endocarditis. J Antimicrob Chemother 1987 Sep: 20 Suppl. A: 173-80
9. Kaye D. Changing pattern of infective endocarditis. Am J Med 1985 Jun 28; 78 (6B): 157-62
10. Wilson WR, Danielson GK, Giuliani ER, et al. Prosthetic valve endocarditis. Mayo Clin Proc 1982 Mar; 57: 155-61
11. Scheld M. Pathogenesis and pathophysiology of infective endocarditis. In: Sande MA, Kaye D, Root RK, editors. Endocarditis. New York: Churchill Livingstone, 1984: 1-32
12. Bush LM, Johnson CC. Clinical syndrome and diagnosis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 99-115
13. Bayer AS. Staphylococcal bacteremia and endocarditis: state of the art. Arch Intern Med 1982; 142: 1169-76
14. Chambers HF, Korzeniowski OM, Sande MA, et al. Staphylococcus aureus endocarditis: clinical manifestation in addicts and non-addicts. Medicine 1983; 62: 170-7
15. Weinstein L, Rubin RH. Infective endocarditis 1973. Progr Cardiovasc Dis 1973; 16: 239-74
16. Sandre RG, Shafran SD. Infective endocarditis: review of 135 cases over 9 years. Clin Infect Dis 1996; 22: 276-86
17. Garvey GJ, Neu HC. Infective endocarditis - an evolving disease: a review of endocarditis at the Columbia Presbyterian Medical Center, 1968-1973, Medicine 1978; 57: 105-27
18. Chambers HF, Miller RT, Newman MD. Right-sided Staphylococcus aureus endocarditis in intravenous drug abusers: two-week combination therapy. Ann Intern Med 1988 Oct 15; 109: 619-24
19. Dinubile MJ. Surgery in active endocarditis. Ann Intern Med 1982 May; 96: 650-9
20. Wilson WR, Danielson GK, Giuliani ER, et al. Valve replacement in patients with active infective endocarditis. Circulation 1978; 58 (4): 585-8
21. Croft CH, Woodward W, Elliott A, et al. Analysis of surgical versus medical therapy in active complicated native valve infective endocarditis. Am J Cardiol 1983 Jun; 51 (10): 1650-5
22. Pelletier IL, Petersdorf RG. In fective endocarditis: a review of 125 cases from the University of Washington Hospital. 1963-72. Medicine 1977; 56: 287-313
23. Churchill MA, Geraci JE, Hunder GG. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 1977; 87: 754-9
24. Irvin RG, Sade RM. Endocarditis and musculoskeletal manifestations. Ann Intern Med 1978; 88: 573-8
25. Steckelberg JM, Murphy JG, Ballard D, et al. Emboli in infective endocarditis: the prognostic value of echocardiography. Ann Intern Med 1991; 114: 635-40
26. Carbone E, Nagel C, Stamboulian D, et al. Endocarditis infecciosa de válvula nativa: evaluación de 204 casos en relación al microorganismo causal. VI Congreso Panamericano de Infectología: X Congreso Chileno de Infectología: 1993 May 26-29; Viña del Mar, Chile
27. Johnson D. The clinical syndrome. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 87-100
28. Francioli P. Central nervous system complications of infective endocarditis. In: Scheld WM, Whitley RJ, Durack DT, editors. Infections of the central nervous system. New York: Raven Press, 1991: 515-59
29. Wilson WR, Liezt Hoset DW, Piepgras DC, et al. The management of patients with mycotic aneurism. Curr Clin Top Infect Dis 1981; 2: 151-83
30. Anderson CB, Butcher HR, Ballinger WF. Mycotic aneurysms. Arch Surg 1974; 109: 712-7
31. Messner RP, Laxdal IT, Quie PG, et al. Rheumatoid factors in subacute bacterial endocarditis - bacterium, duration of disease or genetic predisposition. Ann Intern Med 1968; 68: 747-56
32. McCartney AC, Orange GU, Pringles D, et al. Serum C-reactive protein in infective endocarditis. J Clin Pathol 1988; 41: 44-8
33. Reller LB. Laboratory procedures in the management of infective endocarditis. In: Bisno AL, editor. Treatment of infective endocarditis. New York: Grunnen Stratton, 1981: 235-67
34. Kay KM, Kay D. Laboratory findings including blood cultures. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 117-24
35. Kaye D. Enterococci: biologic and epidemiologic characteristics and in vitro susceptibility. Arch Intern Med 1982; 142: 1006-9
36. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service [see comments]. Am J Med 1994 Mar; 96: 200-9
37. Bayer AS, Ward JI, Ginzton LE, et al. Evaluation of new clinical criteria for the diagnosis of infective endocarditis [see comments]. Am J Med 1994 Mar; 96: 211-9
38. Washington JA. Blood cultures: an overview [editorial]. Eur J Clin Microbiol Infect Dis 1989; 9: 803-6
39. Gotschik E. Microbiological guidelines for the diagnosis and follow up of infective endocarditis. International Society of Chemotherapy. 18th international Congress of Chemotherapy. Stockholm, 1993 Jun 27 to Jul 2
40. Saccente M, Cobbs CG. Clinical approach to infective endocarditis. Cardiol Clin 1996 Aug; 14: 351-62
41. Van-Scoy RE. Culture-negative endocarditis. Mayo Clin Proc 1982 Mar; 57: 149-54
42. Wilson WR, Nichols DR, Thomson R, et al. Infective endocarditis. Am Health J 1980; 100 (5): 689-704
43. Oakley CM. The medical treatment of culture-negative infective endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 90-3
44. Cannady Jr PB, Usar MC, Sanford JP. Negative blood cultures in infective endocarditis: a review. South Med J 1976; 69 (11): 1420-4
45. Pesanti EL, Smith IM. Infective endocarditis with negative blood culture: an analysis of 52 cases. Am J Med 1979; 66: 43-50
46. Siller KA, Johnson WA. Unusual bacterial causes of endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press; 1992: 265-7
47. Spach DH, Callis KP, Paauw DS, et al. Endocarditis caused by Rochalimaea quintana in a patient infected with human immunodeficiency virus. J Clin Microbiol 1993 Mar; 31 (3): 692-4
48. Fernandez-Guerrero ML. Zoonotic endocarditis. Infect Dis Clin North Am 1993 Mar; 7 (1): 135-52
49. Jalava J, Kotilainen P, Nikkari S, et al. Use of the polymerase chain reaction and DNA sequencing for detection of Bartonella quintana in the aortic valve of a patient with culture-negative infective endocarditis. Clin Infect Dis 1995; 21: 891-6
50. Gurpreet SK, Maniet AR. Echocardiographic findings in infective endocarditis. Curr Op Infect Dis 1992; 5: 642-6
51. Buda AJ, Zotz RJ, LeMire MS, et al. Prognostic significance of vegetations detected by two-dimensional echocardiography in infective endocarditis. Am Heart J 1986; 112: 1291-6
52. Daniel WG, Mugge A, Martin RP, et al. Improvement in the diagnosis of abscesses associated with endocarditis by trans- esophageal echocardiography. N Engl J Med 1991; 324: 795-800
53. Besnier JM, Choutel P. Medical treatment of infective endocarditis: general principles. Eur Heart J 1995 Apr; 16 Suppl. B: 72-4
54. Patton JP. Infective endocarditis: economic considerations. In: Kaye D. editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 413-22
55. Stamboulian D. Outpatient treatment of endocarditis in a clinic-based program in Argentina. Eur J Clin Microbiol Infect Dis 1995; 14: 648-54
56. Wilson WR, Thompson RL, Wilkonske C, et al. Short-term therapy for streptococcal infective endocarditis: combined intramuscular administration of penicillin and streptomycin. JAMA 1981; 245: 360-3
57. Bisno AL, Dismukes WE, Durack DT, et al. Antimicrobial treatment of infective endocarditis due to viridans streptococi, enterococci, and staphylococci [see comments]. JAMA 1989 Mar 10; 261: 1471-7
58. Roberts SA, Lang SDR, Ellis-Pegler RB. Short-course treatment of penicillin-susceptible viridans streptococcal infective endocarditis with penicillin and gentamicin. Infect Dis Clin Pract 1993; 2: 191-4
59. Wilson W, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci and HACEK microorganisms. JAMA 1995; 274: 1706-13
60. Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am 1993; 17: 313-22
61. Francioli P, Etienne J, Hoigne R, et al. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks: efficacy and outpatient treatment feasibility [comment]. JAMA 1992 Jan 8; 267: 264-7
62. Stamboulian D, Bonvehí P, Arevalo C, et al. Antibiotic management of outpatients with endocarditis due to penicillin-susceptible streptococci. Rev Infect Dis 1991; 13 Suppl. 2: S160-3
63. Francioli P, Ruch W, Stamboulian D, et al. Treatment of streplococcal endocarditis with single daily dose of ceftriaxone and netilmicin for 14 days: a prospective multicentre study. Clin Infect Dis 1995; 21: 1406-10
64. Stamhoulian D, Carbone E, Nagel C, et al. Ceftriaxone (CRO) in the outpatient treatment of bacterial endocarditis (BE) [abstract no. 10.064]. Presented at the 3rd International Symposium on Modern Concepts in Endocarditis: 1995: Boston, 1995 Jul 13-15
65. Stamhoulian D, Carbone E, Lorenzo L, et al. Ceftriaxone followed by oral amoxicillin in the treatment of penicillin susceptible streptococcal endocarditis [abstract]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22-24; Yverdon-les-Bains, Switzerland
66. Stamhoulian D, Carbone E, Pan M. Ambulatory management of infective endocarditis (IE): pharmacoeconomic considerations [abstract no. 173]. Presented at the 4th International Symposium of Modern Concepts in Endocarditis and Cardiovascular Infections: 1997 May 22-24; Yverdon-les-Bains, Switzerland
67. Sexton D, Tenebaum M, Wilson W, et al. Ceftriaxone once daily for four weeks vs. ceftriaxone plus gentamicin for 2 weeks for the treatment of penicillin-susceptible streptococcal endocarditis [abstract no. 157]. Presented at the 34th Annual Meeting of the Infectious Diseases Society of America. New Orleans, 1996 Sep 18-20
68. Lewis PJ, Martino P, Mosconi G, et al. Teicoplanin in endocarditis: a multicentre, open European study. Chemotherapy 1995; 41: 399-411
69. Schmit JL. Efficacy of teicoplanin for enterococcal infections: 63 cases and review. Clin Infect Dis 1992 Aug; 15 (2): 302-6
70. Kaye D. Treatment of infective endocarditis [editorial]. Ann Intern Med 1996 Mar 15; 124: 606-8
71. Murray BE. The life and times of the enterococcus. Clin Microbiol Rev 1990; 3: 46-65
72. Eliopoulos GM. Aminoglycoside-resistant enterococcal endocarditis. Infect Dis Clin North Am 1993; 7: 117-33
73. Coudron PE, Markowitz SM, Wong ES. Isolation of a betalactamase-producing, aminoglycoside-resistant strain of Enterococcus faecium. Antimicrob Agents Chemother 1992 May; 36: 1125-6
74. Derlot E, Courvalin P. Mechanisms and implications of glycopeptide resistance in enterococci. Am J Med 1991 Sep 16; 91 (3B): 82S-5S
75. Sheagren JN. Staphylcoccus aureus: the persistent pathogen (first of two parts). N Engl J Med 1984 May 24; 310: 1368-73
76. Chambers HF. Short-course combination and oral therapies of Staphylococcus aureus endocarditis. Infect Dis Clin North Am 1993; 7: 69-80
77. Kaye D. Treatment of staphylococcal endocarditis. In: Sande MA, Kaye D, Root RK, editors. Contemporary issues in infectious diseases. New York: Churchill Livingstone, 1984: 135-49
78. Bayer AS, Lam K, Ginzton L, et al. Staphylococcus aureus bacteremia: clinical, serologic, and echocardiographic findings in patients with and without endocarditis. Arch Intern Med 1987 Mar; 147: 457-62
79. Karchmer AW. Staphylococcal endocarditis. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press; 1992: 225-49
80. Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by grampositive bacteria. J Antimicrob Chemother 1993 May; 31 (5): 755-66
81. Martino P, Venditti M, Micozzi A, et al. Teicoplanin in the treatment of gram-positive-bacterial endocarditis. Antimicrob Agents Chemother 1989 Aug; 33 (8): 1329-34
82. Zaki Ali M, Bidwell Goetz M. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809
83. Bailey TC, Russell Little J, Littenberg B, et al. Meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95
84. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis [see comments] Ann Intern Med 1991 Nov 1; 115 (9): 674-80
85. Gopal V, Bisno AL, Silverblatt FJ. Failure of vancomycin treatment in Staphylacoccus aureus endocarditis. In vivo and in vitro observations. JAMA 1976 Oct 4; 236 (14): 1604-6
86. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob Agents Chemother 1990 Jun; 34 (6): 1227-31
87. Bayer A, Lam K. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus in vitro-in vivo correlations. J Infect Dis 1985 Jan; 151 (1): 157-65
88. Bille J. Medical treatment of staphylococcal infective endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 80-3
89. Torres-Tortosa M, de-Cueto M, Vergara A, et al. Prospective evaluation of a two-week course of intravenous antibiotics in intravenous drag addicts with infective endocarditis: Grupo de Estudio de Enfermedades Infecciosas de la Provincia de Cadiz. Eur J Clin Microbiol Infect Dis 1994 Jul; 13: 559-64
90. Dworkin RJ, Lee BL, Sande MA, et al. Treatment of right-sided Staphylococcus aureus endocarditis in intravenous drug users with ciprofloxacin and rifampicin [see comments]. Lancet 1989 Nov 4; 2: 1071-3
91. Tebas P, Martinez Ruiz R, Roman F, et al. Early resistance to rifampin and ciprofloxacin in the treatment of right-sided Staphylococcus aureus endocarditis [letter]. J Infect Dis 1991; 163: 204-5
92. Heldman AW, Hartet T, Ray S, et al. Oral antibiotic treatment of right sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. Am J Med 1996; 101: 68-76
93. Levine D. Clinafloxacin therapy for infective endocarditis [abstract no. 174]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections: 1997 May 22-24: Yverdon-les-Bains, Switzerland
94. Entenza J, Vovillamoz J, Giddey M, et al. Levofloxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible Staphylococcus aureus susceptible or resistant to methicillin (MSSA and MRSA) [abstract no. 157]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections. 1997 May 22-24; Yverdon-les-Bains, Switzerland
95. Entenza J, Vovillamoz J, Giddey M, et al. Trovafloxacin treatment of experimental endocarditis due to ciprofloxacin-susceptible methicillin-resistant Staphylococcus aureus. [abstract no. 159]. Presented at the 4th International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections; 1997 May 22-24; Yverdon-les-Bains, Switzerland
96. Gavalda J, Laguarda M, Capdevila JA, et al. Ceftriaxone (CRO) plus gentamicin (G) once-a-day for treatment (Rx) of Staphylococcus aureus (SA) experimental endocarditis [abstract no. B44]. Presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: San Francisco, 1995 Sep 17-20
97. Lynn DJ, Kane JG, Parker RH. Haemophilus parainfluenzae and influenzae endocarditis: a review of forty cases. Medicine 1977; 56: 115-28
98. Geraci JE, Wilson WR. Symposium on infective endocarditis: III. Endocarditis due to gram-negative bacteria: report of 56 cases. Mayo Clin Proc 1982 Mar; 57: 145-8
99. Reller LB, Baines RD, Brandt D, et al. Activity of ceftriaxone against HACEK bacteria and efficacy in treatment of Haemophilus spp. endocarditis [abstract no. 120]. Presented at the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington. 1987 Oct
100. Rubinstein E, Lang R. Fungal endocarditis. Eur Heart J 1995 Apr; 16 Suppl. B: 84-9
101. Levison ME. Therapy of endocarditis due to gram-negative bacteria and fungi. In: Sande MA, Kaye D, Root RK, editors. Endocarditis. New York: Churchill Livingstone, 1984: 151-61
102. Record CO, Skinner JM, Speight P, et al. Candida endocarditis treated with 5-fluorocytosine. BMJ 1971; 1: 262-4
103. Ivert TS, Dismukes WE, Cobbs CG, et al. Prosthetic valve endocarditis. Circulation 1984; 69: 223-32
104. Calderwood SB, Swinski LA, Karchmer AW, et al. Prosthetic valve endocarditis: analysis of factors affecting outcome of therapy. J Thorac Cardiovasc Surg 1986 Oct; 92: 776-83
105. Karchmer AW, Bisno AL. Infections of prosthetic heart valves and vascular grafts. In: Bisno AL, Waldvogel FA, editors. Infections associated with indwelling medical devices. Washington, DC: American Society for Microbiology, 1989: 129-58
106. Douglas J, Cobbs G. Prosthetic valve endocarditis. In: Kaye D, editor. Infective endocarditis, 2nd ed. New York: Raven Press, 1992: 375-96
107. Nagel C, Carbone R, Argüello E, et al. Endocarditis protésica (EP): evaluatión de 75 casos en relación at microorganismo causal. VI Congreso Panamericano de Infectología: X Congreso Chileno de Infectologia; 1993 May 26-29; Viña del Mar, Chile
108. Whitener C, Caputo GM, Weitekamp MR, et al. Endocarditis due to coagutase-negative staphylococci: microbiologic, epidemiologic, and clinical considerations. Infect Dis Clin North Am 1993 Mar; 7: 81-96
109. Karchmer AW, Archer GL. The National Collaborative Endocarditis Study Group: methicillin resistant Staphylococcus epidermidis prosthetic valve endocarditis. A therapeutic trial [abstract no. 476]. Presented at the 24th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1984 Oct: Washington, DC
110. Kobasa WD, Kaye KL, Shapiro T, et al. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983 Jul-Aug; 5 Suppl. 3: S533-7
111. Chuard C, Herrmenn M, Vaudaux P, et al. Successful therapy of experimental chronic foreign-body infection due lo methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991 Dec; 35 (12): 2611-6
112. Baldassarre JS, Kaye D. Principles and overview of antibiotic therapy. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992; 169-90
113. Santoro J, Ingerman M. Response lo therapy relapses and reinfections. In: Kaye D, editor. Infective endocarditis. 2nd ed. New York: Raven Press, 1992: 423-33
114. Tornos MP, Permanyer-Miralda G, Olona M, et al. Long-term complications of native valve infective endocarditis in nonaddicts: a 15-year follow-up study [see comments]. Ann Intern Med 1992 Oct 1: 117: 567-72
115. Malquarti V, Saradarian W, Etienne J, et al. Prognosis of native valve infective endocarditis: a review of 253 cases. Eur Heart J 1984 Oct; 5 Suppl. C: 11-20
116. Arbulu A, Asfaw I. Management of infective endocarditis: seventeen years' experience. Ann Thorac Surg 1987 Feb; 43: 144-9
117. Davis RS, Strom JA, Frishman W, et al. The demonstration of vegetations by echocardiography in bacterial endocarditis, an indication for early surgical intervention. Am J Med 1980; 69: 57-63
118. ISC Endocarditis Commission Report. Bacterial endocarditis: indications for surgery. 3rd International Symposium on Endocarditis: 1995; Boston (MA)
119. Dajani AS, Bisno AL, Chung KJ, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1990; 264: 2919-22
120. Simmons NA. Recommendations from the endocarditis working party of the British Society for Antimicrobial Chemotherapy: antibiotic prophylaxis of infective endocarditis. Lancet 1990; 335: 88-9
121. Lacassin F, Hgen B, Leport C, et al. Procedures associated with infective endocarditis in addicts. Eur Heart J 1995; 16: 1968-74
122. Horstkotte D, Sick P, Bricks W, et al. Effectiveness of antibiotic prophylaxis to prevent prosthetic valve endocarditis: evidences in humans [abstract]. J Am Coll Cardiol 1991; 17: 212A
123. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA 1997; 277 (22): 1794-801
124. Freedman LR. To prevent or not to prevent bacterial endocarditis - that is the question! [editorial: comment]. Clin Infect Dis 1993 Aug: 17 (2): 195-7
125. Durack DT. Prophylaxis of infective endocarditis. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 716-20
126. Delaye J, Etienne J, Feruglio GA, et al. Prophylaxis of infective endocarditis for dental procedures: report of a working party of the European Society of Cardiology. Eur Heart J 1985; 6: 826-8
127. Weitekamp MR, Caputo GM. Antibiotic prophylaxis: update on common clinical uses. Am Fam Phys 1993 Sep 15; 48: 597-604
128. Van Meer Meer JT. Prevention of bacterial endocarditis: current practice in The Netherlands: Netherlands Heart Foundation. Eur Heart J 1995 Apr; 16 Suppl. B: 114-6
129. Imperiale TF, Hornitz RF. Does prophylaxis prevent post dental infective endocarditis? Am J Med 1990; 88: 131-6
130. Wahl MJ. Myths of dental-induced endocarditis (sec comments]. Arch Intern Med 1994 Jan 24; 154: 137-44
131. Uyemura MC. Antibiotic prophylaxis for medical and dental procedures: a look at AHA guidelines and controversial issues. Postgrad Med 1995 Aug; 98: 137-40, 147, 151-2, passim
132. Bor DH, Himmelstein DU. Endocarditis prophylaxis for patients with mitral valve prolapse: a quantitative analysis. Am J Med 1984 Apr; 76: 711-7
133. Clemens JD, Ransohoff DF. A quantitative assessment of predental antibiotic prophylaxis for patients with mitral-valve prolapse. J Chronic Dis 1984; 37 (7): 531-44
134. Leport C, Horstkotte D, Burckhardt D. Antibiotic prophylaxis for infective endocarditis from an international group of experts towards a European consensus. Group of experts of the International Society for Chemotherapy. Eur Heart J 1995 Apr; 16 Suppl. B: 126-31
135. Everett ED, Hirschmann TU. Transient bacteremia and endocarditis prophylaxis: a review. Medicine (Baltimore) 1977; 56: 61-77
136. Danchin N. The prophylaxis of infective endocarditis: current practices in France. French Federation of Cardiology. Eur Heart J 1995 Apr; 16 Suppl. B: 122-5
137. Gutschik E. Prevention of endocarditis in the Nordic countries. Eur Heart J 1995 Apr; 16 Suppl. B: 117-21
138. Dajani AS, Bawdon RE, Berry MC Oral amoxicillin as prophylaxis for endocarditis: what is the optimal dose? Clin Infect Dis 1994 Feb; 18(2): 157-60
139. Rahn R, Schafer V, Shah PM, Kees F, Macrolides in the prophylaxis for endocarditis [abstract no. 108]. 6th International Congress for Infectious Diseases: Prague, 1994 April 26-30
140. Durack DT, Littler WA. Failure of adequate penicillin therapy to prevent bacterial endocarditis after tooth extraction. Lancet 1974; 11: 846-7
141. Durack DT, Kaplan EL, Bisno AL. Apparent failures of endocarditis prophylaxis: analysis of 52 cases submitted to a national registry. JAMA 1983 Nov 4; 250: 2318-22
142. Schöneberger A, Raschka C, Zurkorrekten Durchführung der Endocarditis-Prophylaxe. Herz Kriesl 1992; 24: 117-8
143. Brooks SL. Survey of compliance with American Heart Association guidelines to prevention of bacterial endocarditis. J Am Dent Assoc 1980; 101: 41-3
144. Eykyn SJ. Les protocoles actuels de prophylaxie de l'endocardite infectieuse. Med Mal Infect 1992; 22 Spécial: 1056-60